{"paper_id":"eb9c3169-a36c-435a-a794-704eafb9cbfb","body_text":"References\nOzer H, Boztosun A, Açmaz G, et al. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model [published online August 15, 2012]. Reprod Sci. 2012.\nFerrero S, Ragni N, Remorgida V. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006;149(2):133–135.\nItoga T, Matsumoto T, Takeuchi H, et al. Fibrosis and smooth muscle metaplasia in rectovaginal endometriosis. Pathol Int. 2003;53(6):371–375.\nMorotti M, Valenzano Menada M, Venturini PL, Ferrero S. Bevacizumab in endometrial cancer treatment. Expert Opin Biol Ther. 2012;12(5):649–658.\nGressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490–501.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nMorotti, M., Ferrero, S. Antiangiogenic Drugs in the Treatment of Endometriosis. Reprod. Sci. 20, NP1–NP2 (2013). https://doi.org/10.1177/1933719112468955\nPublished:\nIssue date:\nDOI: https://doi.org/10.1177/1933719112468955","source_license":"CC0","license_restricted":false}